Recommendation on Continuing Amitriptyline and Betahistine After One Year Vertigo-Free
Given that you have been vertigo-free for one year, it is reasonable to discontinue or taper both medications, particularly betahistine, as the evidence does not support long-term continuation once symptoms have resolved.
Rationale for Discontinuation
Betahistine (Zapis)
The 2020 American Academy of Otolaryngology Clinical Practice Guideline for Ménière's Disease explicitly recommends that clinicians and patients discuss titrating down or stopping betahistine once symptoms subside 1. The guideline emphasizes:
- The landmark BEMED trial (the highest quality evidence available) showed no significant difference between betahistine and placebo in controlling vertigo attacks over 9 months 1
- There are no clear data suggesting how long betahistine should be used, with most studies covering only 2-12 weeks, and the longest covering 9 months 1
- The natural history of vertigo shows significant decline across all groups over time, including placebo 1
Since you've been symptom-free for a full year, continuing betahistine offers no proven benefit and only exposes you to potential side effects (headache, nausea, palpitations, gastrointestinal symptoms) 1.
Amitriptyline (Eliwel) 0.25 mg
Your dose of 0.25 mg is extraordinarily low—far below any studied therapeutic range. According to the FDA label, even the lowest recommended doses for any indication start at 10 mg three times daily for adolescents and elderly patients 2. Real-world headache studies show most patients use 10-25 mg daily 3.
At 0.25 mg, you are receiving a sub-therapeutic dose that likely provides only placebo effect. The FDA label specifically states that maintenance therapy should be reduced to the lowest amount that maintains symptom relief, and when satisfactory improvement is reached, dosage should be reduced 2.
Clinical Algorithm for Decision-Making
Step 1: Assess Current Status
- Vertigo-free duration: 1 year ✓
- Any residual symptoms: None implied
- Medication side effects: Not mentioned but possible
Step 2: Taper Betahistine First
- Discontinue betahistine immediately (no taper needed for this medication)
- Monitor for 2-4 weeks for any vertigo recurrence
Step 3: Discontinue Amitriptyline
- Given the extremely low dose (0.25 mg), discontinuation can be immediate without taper
- At therapeutic doses, gradual taper would be recommended, but this dose is negligible
Step 4: Monitoring Plan
- Watch for vertigo recurrence over next 3 months
- If symptoms return, consider non-pharmacological interventions first (vestibular rehabilitation, dietary modifications)
- Restart medication only if symptoms significantly impact quality of life
Important Caveats
Common pitfall: Patients and providers often continue medications indefinitely "because they're working," when in reality the natural disease course has resolved. The guideline evidence shows vertigo attacks decline naturally over time regardless of treatment 1.
Safety consideration: While betahistine is generally well-tolerated, a rare 2026 case report documented betahistine-associated suicidality and depression 4. Though uncommon, continuing unnecessary medication exposes you to preventable risks.
Quality of life: Continuing medications you don't need can impact daily functioning (potential sedation from amitriptyline, even at low doses), create unnecessary medication burden, and incur costs without benefit.
The evidence strongly supports discontinuation in your specific situation—one year symptom-free with no clear indication for prophylaxis. Your provider's suggestion to continue may reflect conservative practice, but the highest quality guideline evidence recommends stopping medications once symptoms resolve 1.